Hansa Biopharma AB (publ) (LON:0RC7)
London flag London · Delayed Price · Currency is GBP · Price in SEK
40.00
+3.64 (10.01%)
At close: Feb 11, 2026

Hansa Biopharma AB Balance Sheet

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
701.08405.28732.061,496651.34
Short-Term Investments
----237.62
Cash & Short-Term Investments
701.08405.28732.061,496888.96
Cash Growth
72.99%-44.64%-51.07%68.31%-35.47%
Accounts Receivable
53.87144.9778.0342.969.71
Other Receivables
35.5217.4915.7324.2213.53
Receivables
89.4162.4693.7667.1823.24
Inventory
6.132.611.510.970.24
Prepaid Expenses
-2.843.063.523.34
Other Current Assets
-12.2424.7636.8526.56
Total Current Assets
796.61585.43855.151,605942.34
Property, Plant & Equipment
13.3517.8827.0735.8441.71
Other Intangible Assets
230.5620.4623.1726.0128.76
Long-Term Accounts Receivable
126.25----
Long-Term Deferred Charges
-176.88112.6520.85-
Total Assets
1,167800.641,0181,6871,013
Accounts Payable
66.2937.6286.9762.4853.36
Accrued Expenses
121.1497.89116.54100.3278.22
Short-Term Debt
136.87----
Current Portion of Leases
8.287.687.57.176.89
Current Income Taxes Payable
1.832.711.60.6-
Current Unearned Revenue
-16.3341.4740.4324.96
Other Current Liabilities
76.2693.4566.9153.717.79
Total Current Liabilities
410.66255.69320.99264.71171.22
Long-Term Debt
785.681,065844.9762.6-
Long-Term Leases
36.6814.3621.3328.49
Long-Term Unearned Revenue
1.61--29.547.02
Long-Term Deferred Tax Liabilities
0.260.170.370.410.43
Other Long-Term Liabilities
49.7163.35.35.958.08
Total Liabilities
1,2511,3901,1861,084255.24
Common Stock
-84.1367.8155.0355.0346.34
Additional Paid-In Capital
-3,4513,0833,0222,573
Retained Earnings
--4,110-3,303-2,471-1,860
Treasury Stock
---2.36-2.59-1.86
Comprehensive Income & Other
-0.94-0.410.010.13
Shareholders' Equity
-84.13-589.83-167.88602.91757.57
Total Liabilities & Equity
1,167800.641,0181,6871,013
Total Debt
933.821,079866.77791.0935.38
Net Cash (Debt)
-232.73-673.73-134.71705.09853.58
Net Cash Growth
----17.40%-37.81%
Net Cash Per Share
-2.87-10.72-2.5615.7019.19
Filing Date Shares Outstanding
101.7667.8152.6752.4444.47
Total Common Shares Outstanding
101.7667.8152.6752.4444.47
Working Capital
385.95329.74534.161,340771.12
Book Value Per Share
-0.83-8.70-3.1911.5017.03
Tangible Book Value
-314.7-610.29-191.05576.9728.81
Tangible Book Value Per Share
-3.09-9.00-3.6311.0016.39
Source: S&P Global Market Intelligence. Standard template. Financial Sources.